Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01996098 | Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation(ICTAN) | terminated | Phase 3 | 251 | Sun Yat-sen UniversityOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT03056638 | Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer | terminated | Phase 3 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 28, 2024 |
| NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant(SBRTvsTACE) | terminated | Phase 3 | 9 | Lahey ClinicOTHER | 2 | Aug 28, 2024 | clinicaltrials |
| NCT04849858 | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures | terminated | Phase 3 | 13 | University of California, IrvineOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer(IMpassion030) | terminated | Phase 3 | 2,199 | Hoffmann-La RocheINDUSTRY | 31 | Aug 21, 2024 | clinicaltrials |
| NCT05223673 | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer(COLSTAR) | terminated | Phase 3 | 7 | Institut de Recherches Internationales ServierOTHER | 6 | Aug 20, 2024 | clinicaltrials |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 3 | 104 | Hinova Pharmaceuticals USA, Inc.INDUSTRY | 14 | Aug 19, 2024 | clinicaltrials |
| NCT00113256 | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | terminated | Phase 2 / Phase 3 | 39 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04395339 | GM1 Prophylaxis for WBRT Related Cognitive Dysfunction(GLORY) | terminated | Phase 3 | 51 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05239663 | GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer | terminated | Phase 3 | 76 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03616470 | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 3 | 388 | GlycoMimetics IncorporatedINDUSTRY | 9 | Jul 29, 2024 | clinicaltrials |
| NCT03233828 | Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2(IL-2) | terminated | Phase 3 | 1 | Carman GiacomantonioOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04907227 | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension | terminated | Phase 3 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 12, 2024 | clinicaltrials |
| NCT04128696 | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-3) | terminated | Phase 3 | 315 | GlaxoSmithKlineINDUSTRY | 26 | Jul 10, 2024 | clinicaltrials |
| NCT04656262 | Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients(METROPHOLYS) | terminated | Phase 3 | 79 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT02974426 | To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer | terminated | Phase 3 | 132 | Shanghai Chest HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ATLAS) | terminated | Phase 3 | 282 | UroGen Pharma Ltd.INDUSTRY | 10 | Jun 6, 2024 | clinicaltrials |
| NCT03887702 | Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors | terminated | Phase 3 | 4 | SWOG Cancer Research NetworkNETWORK | 2 | May 20, 2024 | clinicaltrials |
| NCT05207514 | Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | terminated | Phase 3 | 26 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | terminated | Phase 3 | 48 | QED Therapeutics, a BridgeBio companyINDUSTRY | 15 | May 8, 2024 | clinicaltrials |
| NCT05493501 | Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer | terminated | Phase 3 | 8 | EQRx International, Inc.INDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)(ULTRA-V) | terminated | Phase 2 / Phase 3 | 277 | TG Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer | terminated | Phase 3 | 1 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia(AML) | terminated | Phase 3 | 9 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03866980 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer | terminated | Phase 3 | 164 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT00310232 | Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) | terminated | Phase 3 | 70 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04300114 | A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | terminated | Phase 3 | 5 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT03699956 | RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer(REPLATINUM) | terminated | Phase 3 | 18 | EpicentRx, Inc.INDUSTRY | 1 | Mar 26, 2024 | clinicaltrials |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations(PROOF302) | terminated | Phase 3 | 39 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT04816214 | Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy(GEOMETRY-E) | terminated | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 5, 2024 | clinicaltrials |
| NCT05065411 | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer(VERU-024) | terminated | Phase 3 | 5 | Veru Inc.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04780464 | A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma(Tolerance) | terminated | Phase 3 | 14 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT03275402 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases | terminated | Phase 2 / Phase 3 | 52 | Y-mAbs TherapeuticsINDUSTRY | 4 | Feb 13, 2024 | clinicaltrials |
| NCT04460807 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer(EXPERT) | terminated | Phase 3 | 23 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04409223 | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | terminated | Phase 3 | 185 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent(VERACITY) | terminated | Phase 3 | 105 | Veru Inc.INDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT02654587 | OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure(ATALANTE-1) | terminated | Phase 3 | 219 | OSE ImmunotherapeuticsINDUSTRY | 10 | Feb 2, 2024 | clinicaltrials |
| NCT00617656 | Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma(BREC) | terminated | Phase 3 | 382 | Spanish Lung Cancer GroupOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03151811 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide(OCEAN) | terminated | Phase 3 | 495 | Oncopeptides ABINDUSTRY | 21 | Jan 30, 2024 | clinicaltrials |
| NCT00630565 | Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 / Phase 3 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04869943 | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer(ARTEST) | terminated | Phase 3 | 52 | Veru Inc.INDUSTRY | 4 | Jan 26, 2024 | clinicaltrials |
| NCT03500874 | Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | terminated | Phase 3 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04864782 | QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer | terminated | Phase 2 / Phase 3 | 46 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03138499 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,(CheckMate 812) | terminated | Phase 3 | 23 | Bristol-Myers SquibbINDUSTRY | 3 | Jan 10, 2024 | clinicaltrials |
| NCT04409288 | Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer | terminated | Phase 3 | 74 | Chinese University of Hong KongOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04592861 | Carbon Ion RT for Locally Advanced Pancreatic Cancer | terminated | Phase 3 | 5 | Albert Einstein College of MedicineOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04970368 | Comparison of Nodal Staging in Endometrial Cancer | terminated | Phase 3 | 38 | Frederick R. Ueland, M.D.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin | terminated | Phase 3 | 16 | GlaxoSmithKlineINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(RELIANT) | terminated | Phase 3 | 43 | Corcept TherapeuticsINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 5, 2024source: clinicaltrials